Article: New therapeutics highlighted at ARVO

An overview

Studies show improvement in patients with AMD, dry eye, lid margin disease, and other conditions

This year's annual gathering for the Association for Research in Vision and Ophthalmology (ARVO) meeting in Fort Lauderdale, FL1 produced an array of posters and sessions on all the therapeutic areas. In this review, we'll take a look at the presentations that we considered to be highlights of ARVO 2009.

Retina research

Regeneran continues its work on a fusion protein (VEGF Trap-Eye) that binds to all VEGF-A isotbrms and PIGF. Results from the 12-month phase II study (n = 157) in neovascular age-related macular degeneration demonstrated that the drug lowers central retinal thickness, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!